ArriVent to present phase 1 ADC data at ESMO Congress 2026
Tweet Send to a Friend
ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced that initial Phase 1 safety and efficacy data for its CDH17-targeted antibody-drug conjugate ARR-217 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




